A little-known protein guards brain mitochondria after bleeding stroke — in mice

A bleeding stroke kills twice: first the bleed itself, then the slow wave of cell death that follows as mitochondria fail. A new study in Cell Death & Disease (October 9, 2026), from Chongqing Medical University, names a previously unrecognized gatekeeper in that second wave: TSPOAP1, a protein that guards the mitochondrial membrane pore in neurons. When the researchers removed it, the pore snapped open, spilling cytochrome c and driving brain cells to self-destruct — and a drug that raised TSPOAP1 preserved mitochondrial integrity and improved recovery in mice.

Why do brain cells die after the bleeding stops?

In an intracerebral hemorrhage, blood bursts directly into brain tissue. The initial damage is mechanical — but the larger, treatable injury unfolds over hours and days as stressed mitochondria in nearby neurons open a channel called the permeability transition pore. Once that pore opens, cytochrome c escapes into the cell, and the neuron runs its own death program. This secondary wave is where a drug could still intervene.

What does TSPOAP1 actually do?

TSPOAP1 sits at that pore and keeps it shut. The study's twist is the mechanism: the pore involved works through ANT2, a different molecular route than the classic CypD-dependent channel most textbooks describe. That matters because it means the brain's pore machinery after hemorrhage is not the one existing experimental drugs were designed for — the gatekeeper, and the gate, were both partly misidentified.

What did the experiments find?

Mice lacking TSPOAP1 fared worse after induced hemorrhage: more pore opening, more cytochrome c release, more neuronal death. Conversely, a compound that raised TSPOAP1 levels preserved mitochondrial integrity and measurably improved neurological recovery. The human link is early but real — the researchers confirmed TSPOAP1 is depleted in brain tissue from hemorrhage patients, the same direction as the mouse injury.

Why it matters for a disease with almost no drugs

Hemorrhagic stroke is the cruelest corner of stroke medicine: clot-busting drugs do not apply, and surgery helps only some patients. A druggable protein that decides whether neuronal mitochondria live or die — through a pore mechanism the field had overlooked — gives drug developers a concrete new target. The distance to a therapy is years, but the direction is now drawn on the map.

Where the evidence stands

• Established: Hemorrhagic stroke has almost no drug treatments; secondary mitochondrial failure is a known executioner of brain cells after the bleed.
• Preliminary: TSPOAP1's pore-guarding role, the ANT2-linked mechanism, and the recovery benefit of raising TSPOAP1 were shown in mouse hemorrhage models and neuronal cell lines; TSPOAP1 loss was confirmed in human patient brain tissue.
• Absent: Any human intervention data — whether raising TSPOAP1 helps stroke patients is untested.